Vnitr Lek 2000, 46(3):157-160

[Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].

R Ceska, T Kvasnicka, T Haas, V Soska, H Vaverková

Za skupinu spolupracujících center Klinického sledování úcinnosti lipanoru III. interní klinika 1, Praha.

A total of 633 patients with combined hyperlipoproteinaemia from 23 centres in the Czech Republic met the criteria for assessment of the effectiveness of 3-month administration of 100 mg ciprofibrate (Lipanor) per day. The cholesterol concentration declined from the original values of 6.94 mmol/l by 13%. The drop of triglycerides was even more significant from 3.03 mmol/l by more than 41%. The relatively low HDL cholesterol at the beginning, 1.14 mmol/l, increased by 15%, while LDL-cholesterol dropped significantly by almost 12%. The classical atherogenic index expressed by the ratio of total/HDL cholesterol declined by 25%. Treatment was very well tolerated by the patients and was associated with a minimum of undesirable side-effects. Treatment with ciprofibrate is effective and safe treatment in patients with combined hyperlipoproteinaemia.

Keywords: Clofibric Acid, analogs & derivatives, ; Female; Fibric Acids; Humans; Hyperlipoproteinemias, drug therapy, ; Hypolipidemic Agents, therapeutic use, ; Male; Middle Aged

Published: March 1, 2000  Show citation